id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-E-1290-0006,FDA,FDA-2024-E-1290,Determination of Regulatory Review Period for Purposes of Patent Extension; FILSUVEZ,Notice,Determinations,2025-12-10T05:00:00Z,2025,12,2025-12-10T05:00:00Z,2026-02-10T04:59:59Z,2026-02-07T13:13:03Z,2025-22380,0,0,09000064b90c167a
FDA-2024-E-1290-0005,FDA,FDA-2024-E-1290,Letter to U. S. Patent and Trademark Office,Other,Letter(s),2025-08-27T04:00:00Z,2025,8,2025-08-27T04:00:00Z,,2025-08-27T22:22:52Z,,0,0,09000064b8f1b7f7
FDA-2024-E-1290-0004,FDA,FDA-2024-E-1290,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-07-15T04:00:00Z,2025,7,2025-07-15T04:00:00Z,,2025-07-15T19:41:42Z,,0,0,09000064b8e6f0c1
FDA-2024-E-1290-0003,FDA,FDA-2024-E-1290,Letter from FDA CDER to U. S. Patent and Trademark Office,Other,Letter(s),2025-06-30T04:00:00Z,2025,6,2025-06-30T04:00:00Z,,2025-06-30T20:04:37Z,,0,0,09000064b8e43a25
FDA-2024-E-1290-0001,FDA,FDA-2024-E-1290,Letter from U. S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:58:13Z,,0,0,090000648647da37
FDA-2024-E-1290-0002,FDA,FDA-2024-E-1290,"Patent Term Extension Application for FILSUVEZ Patent No 8,828,444",Other,Application,2024-03-18T04:00:00Z,2024,3,2024-03-18T04:00:00Z,,2024-03-18T15:58:16Z,,0,0,090000648647da3d